Abstract
Bone metastases are a common complication in patients with advanced lung cancer, and most patients with bone metastases from lung cancer develop skeletal-related events (SREs). Skeletal-related events adversely impact patient quality of life and clinical outcome and are associated with increased costs of clinical management, underscoring the need for SRE prevention. Because current practice guidelines do not recommend pretreatment bone scans for all patients at initial presentation, skeletal involvement is not detected in a proportion of patients with early stage asymptomatic bone metastases. In addition, there are no uniform guidelines outlining treatment for patients with bone metastases. Although many bisphosphonates have not been investigated in this setting, zoledronic acid has proven efficacy in delaying the onset and reducing the risk of SREs in patients with bone metastases from lung cancer. Further, recent exploratory analyses in patients with bone metastases from solid tumors suggest that, in addition to normalizing biochemical markers of bone metabolism, zoledronic acid may improve survival in specific patient subsets, including those with lung cancer. Accordingly, several prospectively designed clinical trials assessing anticancer activity of zoledronic acid in the adjuvant setting are ongoing. New insights into the clinical relevance of bone-conserving therapy in patients with lung cancer are discussed.
| Original language | English |
|---|---|
| Journal | Seminars in Oncology |
| Volume | 37 |
| Issue number | SUPPL. |
| DOIs | |
| State | Published - Jun 1 2010 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Oncology
- Hematology
Cite this
Bisphosphonates in lung cancer : More than a palliative therapy? / Jahanzeb, Mohammad; Hirsh, Vera.
In: Seminars in Oncology, Vol. 37, No. SUPPL., 01.06.2010.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Bisphosphonates in lung cancer
T2 - More than a palliative therapy?
AU - Jahanzeb, Mohammad
AU - Hirsh, Vera
PY - 2010/6/1
Y1 - 2010/6/1
N2 - Bone metastases are a common complication in patients with advanced lung cancer, and most patients with bone metastases from lung cancer develop skeletal-related events (SREs). Skeletal-related events adversely impact patient quality of life and clinical outcome and are associated with increased costs of clinical management, underscoring the need for SRE prevention. Because current practice guidelines do not recommend pretreatment bone scans for all patients at initial presentation, skeletal involvement is not detected in a proportion of patients with early stage asymptomatic bone metastases. In addition, there are no uniform guidelines outlining treatment for patients with bone metastases. Although many bisphosphonates have not been investigated in this setting, zoledronic acid has proven efficacy in delaying the onset and reducing the risk of SREs in patients with bone metastases from lung cancer. Further, recent exploratory analyses in patients with bone metastases from solid tumors suggest that, in addition to normalizing biochemical markers of bone metabolism, zoledronic acid may improve survival in specific patient subsets, including those with lung cancer. Accordingly, several prospectively designed clinical trials assessing anticancer activity of zoledronic acid in the adjuvant setting are ongoing. New insights into the clinical relevance of bone-conserving therapy in patients with lung cancer are discussed.
AB - Bone metastases are a common complication in patients with advanced lung cancer, and most patients with bone metastases from lung cancer develop skeletal-related events (SREs). Skeletal-related events adversely impact patient quality of life and clinical outcome and are associated with increased costs of clinical management, underscoring the need for SRE prevention. Because current practice guidelines do not recommend pretreatment bone scans for all patients at initial presentation, skeletal involvement is not detected in a proportion of patients with early stage asymptomatic bone metastases. In addition, there are no uniform guidelines outlining treatment for patients with bone metastases. Although many bisphosphonates have not been investigated in this setting, zoledronic acid has proven efficacy in delaying the onset and reducing the risk of SREs in patients with bone metastases from lung cancer. Further, recent exploratory analyses in patients with bone metastases from solid tumors suggest that, in addition to normalizing biochemical markers of bone metabolism, zoledronic acid may improve survival in specific patient subsets, including those with lung cancer. Accordingly, several prospectively designed clinical trials assessing anticancer activity of zoledronic acid in the adjuvant setting are ongoing. New insights into the clinical relevance of bone-conserving therapy in patients with lung cancer are discussed.
UR - http://www.scopus.com/inward/record.url?scp=77955433435&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77955433435&partnerID=8YFLogxK
U2 - 10.1053/j.seminoncol.2010.06.004
DO - 10.1053/j.seminoncol.2010.06.004
M3 - Article
C2 - 20682372
AN - SCOPUS:77955433435
VL - 37
JO - Seminars in Oncology
JF - Seminars in Oncology
SN - 0093-7754
IS - SUPPL.
ER -